Population-Attributable Fractions of Personal Comorbidities for Liver, Gallbladder, and Bile Duct Cancers
Status PubMed-not-MEDLINE Jazyk angličtina Země Švýcarsko Médium electronic
Typ dokumentu časopisecké články
Grantová podpora
856620
European Union Horizon 2020
PubMed
37370702
PubMed Central
PMC10296338
DOI
10.3390/cancers15123092
PII: cancers15123092
Knihovny.cz E-zdroje
- Klíčová slova
- alcohol, bile duct infection, comorbidity, hepatocellular carcinoma, risk factor, viral infection,
- Publikační typ
- časopisecké články MeSH
BACKGROUND: We aim to estimate population-attributable fractions (PAF) for 13 comorbidities potentially predisposing to hepatobiliary cancer of hepatocellular carcinoma (HCC), gallbladder cancer (GBC), cancers of the intrahepatic and extrahepatic bile ducts (ICC and ECC), and ampullary cancer. METHODS: Patients were identified from the Swedish Inpatient Register from 1987 to 2018 and cancers from the Swedish Cancer Registry from 1997 through 2018. PAFs were calculated for each comorbidity-associated cancer using a cohort study design. RESULTS: For male HCC, the major individual comorbidities (PAF > 10) were diabetes, alcohol-related liver disease, and hepatitis C virus infection. For female HCC, diabetes and autoimmune diseases were important contributors. For female GBC, gallstone disease was an overwhelming contributor, with a PAF of 30.57%, which was also important for men. The overall PAF for male ICC was almost two times higher than the female one. For ECC and ampullary cancer, infection of bile ducts was associated with the highest PAF. CONCLUSIONS: The 13 comorbidities accounted for 50% or more of the potential etiological pathways of each hepatobiliary cancer except female ICC. The underlying convergent mechanism for these cancers may be chronic inflammation lasting for decades and thus offering possibilities for intervention and disease monitoring.
Center for Primary Health Care Research Lund University 20502 Malmö Sweden
Comprehensive Cancer Center Helsinki University Hospital 00290 Helsinki Finland
Department of Surgery University Hospital School of Medicine in Pilsen 323 00 Pilsen Czech Republic
Division of Pediatric Neurooncology German Cancer Research Center 69120 Heidelberg Germany
Zobrazit více v PubMed
Valle J.W., Kelley R.K., Nervi B., Oh D.Y., Zhu A.X. Biliary tract cancer. Lancet. 2021;397:428–444. doi: 10.1016/S0140-6736(21)00153-7. PubMed DOI
Villanueva A. Hepatocellular Carcinoma. N. Engl. J. Med. 2019;380:1450–1462. doi: 10.1056/NEJMra1713263. PubMed DOI
Leone V., Ali A., Weber A., Tschaharganeh D.F., Heikenwalder M. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer. 2021;7:606–623. doi: 10.1016/j.trecan.2021.01.012. PubMed DOI
Koshiol J., Yu B., Kabadi S.M., Baria K., Shroff R.T. Epidemiologic patterns of biliary tract cancer in the United States: 2001–2015. BMC Cancer. 2022;22:1178. doi: 10.1186/s12885-022-10286-z. PubMed DOI PMC
Hemminki K., Försti A., Hemminki O., Liska V., Hemminki A. Long-term incidence and survival trends in cancer of the gallbladder and extrahepatic bile ducts in Denmark, Finland, Norway and Sweden with etiological implications related to Thorotrast. Int. J. Cancer. 2022;151:200–208. doi: 10.1002/ijc.33980. PubMed DOI
Hemminki K., Tichanek F., Försti A., Hemminki O., Liska V., Hemminki A. Long-term incidence in hepatocellular carcinoma and intrahepatic bile duct cancer in Denmark, Finland, Norway and Sweden, role of Thorotrast? Int. J. Cancer. 2022;151:510–517. doi: 10.1002/ijc.34031. PubMed DOI
Lazarus J.V., Mark H.E., Anstee Q.M., Arab J.P., Batterham R.L., Castera L., Cortez-Pinto H., Crespo J., Cusi K., Dirac M.A., et al. Advancing the global public health agenda for NAFLD: A consensus statement. Nat. Rev. Gastroenterol. Hepatol. 2022;19:60–78. doi: 10.1038/s41575-021-00523-4. PubMed DOI
Hemminki K., Sundquist K., Sundquist J., Försti A., Liska V., Hemminki A., Li X. Personal comorbidities and their subsequent risks for liver, gallbladder and bile duct cancers. Int. J. Cancer. 2023;152:1107–1114. doi: 10.1002/ijc.34308. PubMed DOI
Hemminki K., Sundquist K., Sundquist J., Försti A., Liska V., Hemminki A., Li X. Familial Risks for Liver, Gallbladder and Bile Duct Cancers and for Their Risk Factors in Sweden, a Low-Incidence Country. Cancers. 2022;14:1938. doi: 10.3390/cancers14081938. PubMed DOI PMC
Liu X., Hemminki K., Forsti A., Sundquist K., Sundquist J., Ji J. Cancer risk in patients with type 2 diabetes mellitus and their relatives. Int. J. Cancer. 2015;137:903–910. doi: 10.1002/ijc.29440. PubMed DOI
Rawla P., Sunkara T., Thandra K.C., Barsouk A. Epidemiology of gallbladder cancer. Clin. Exp. Hepatol. 2019;5:93–102. doi: 10.5114/ceh.2019.85166. PubMed DOI PMC
Biological Agents . IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 100. Internactional Agency for Research on Cancers; Paris, France: 2012. Agents. A review of human carcinogens; pp. 1–441. PubMed PMC
McGee E.E., Jackson S.S., Petrick J.L., Van Dyke A.L., Adami H.O., Albanes D., Andreotti G., Beane-Freeman L.E., Berrington de Gonzalez A., Buring J.E., et al. Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies. J. Natl. Cancer Inst. 2019;111:1263–1278. doi: 10.1093/jnci/djz103. PubMed DOI PMC
Barner-Rasmussen N., Pukkala E., Hadkhale K., Färkkilä M. Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland. United Eur. Gastroenterol. J. 2021;9:1128–1135. doi: 10.1002/ueg2.12154. PubMed DOI PMC
Clements O., Eliahoo J., Kim J.U., Taylor-Robinson S.D., Khan S.A. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J. Hepatol. 2020;72:95–103. doi: 10.1016/j.jhep.2019.09.007. PubMed DOI
Hemminki J., Försti A., Hemminki A., Hemminki K. Survival trends in solid cancers in the Nordic countries through 50 years. Eur. J. Cancer. 2022;175:77–85. doi: 10.1016/j.ejca.2022.08.015. PubMed DOI
Hemminki K., Försti A., Hemminki O., Liska V., Hemminki A. Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries. JHEP Rep. 2022;4:100602. doi: 10.1016/j.jhepr.2022.100602. PubMed DOI PMC
Rutherford M.J., Arnold M., Bardot A., Ferlay J., De P., Tervonen H., Little A., Bucher O., St. Jacques N., Gavin A., et al. Comparison of liver cancer incidence and survival by subtypes across seven high-income countries. Int. J. Cancer. 2021;149:2020–2031. doi: 10.1002/ijc.33767. PubMed DOI
Hemminki K., Försti A., Liska V., Kanerva A., Hemminki O., Hemminki A. Long-term survival trends in solid cancers in the Nordic countries marking timing of improvements. Int. J. Cancer. 2023;152:1837–1846. doi: 10.1002/ijc.34416. PubMed DOI
Nakagawa H., Maeda S. Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J. Gastroenterol. 2012;18:4071–4081. doi: 10.3748/wjg.v18.i31.4071. PubMed DOI PMC
Llovet J.M., Kelley R.K., Villanueva A., Singal A.G., Pikarsky E., Roayaie S., Sangro B., Schwartz M., Sherman M., Gores G. Hepatocellular carcinoma. Nat. Rev. Disease Primers. 2021;7:6. doi: 10.1038/s41572-020-00240-3. PubMed DOI
Li X., Ramadori P., Pfister D., Seehawer M., Zender L., Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat. Rev. Cancer. 2021;21:541–557. doi: 10.1038/s41568-021-00383-9. PubMed DOI
Miettinen O. Proportion of disease caused or prevented by a given exposure, trait or intervention. Am. J. Epidemiol. 1974;99:325–332. doi: 10.1093/oxfordjournals.aje.a121617. PubMed DOI
Dos Santos Silva I. Cancer Epidemiology: Principles and Methods. IARC; Lyon, France: 1999. 442p
Brown K.F., Rumgay H., Dunlop C., Ryan M., Quartly F., Cox A., Deas A., Elliss-Brookes L., Gavin A., Hounsome L., et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br. J. Cancer. 2018;118:1130–1141. doi: 10.1038/s41416-018-0029-6. PubMed DOI PMC
Henriksson M., Björnsson B., Sternby Eilard M., Lindell G., Strömberg C., Hemmingsson O., Isaksson B., Rizell M., Sandström P. Treatment patterns and survival in patients with hepatocellular carcinoma in the Swedish national registry SweLiv. BJS Open. 2020;4:109–117. doi: 10.1002/bjs5.50226. PubMed DOI PMC
Lindberg A., Bjerg A., Rönmark E., Larsson L.G., Lundbäck B. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir. Med. 2006;100:264–272. doi: 10.1016/j.rmed.2005.04.029. PubMed DOI
Thomsen H., Li X., Sundquist K., Sundquist J., Försti A., Hemminki K. Familial risks between Graves disease and Hashimoto thyroiditis and other autoimmune diseases in the population of Sweden. J. Transl. Autoimmun. 2020;3:100058. doi: 10.1016/j.jtauto.2020.100058. PubMed DOI PMC
Rothman K., Greenland S. Modern Epidemiology. 2nd ed. Lippincott-Raven; Philadelphia, PA, USA: 1998.
Rückinger S., von Kries R., Toschke A.M. An illustration of and programs estimating attributable fractions in large scale surveys considering multiple risk factors. BMC Med. Res. Methodol. 2009;9:7. doi: 10.1186/1471-2288-9-7. PubMed DOI PMC
Whiteman D.C., Wilson L.F. The fractions of cancer attributable to modifiable factors: A global review. Cancer Epidemiol. 2016;44:203–221. doi: 10.1016/j.canep.2016.06.013. PubMed DOI
Baecker A., Liu X., La Vecchia C., Zhang Z.F. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur. J. Cancer Prev. 2018;27:205–212. doi: 10.1097/CEJ.0000000000000428. PubMed DOI PMC
Makarova-Rusher O.V., Altekruse S.F., McNeel T.S., Ulahannan S., Duffy A.G., Graubard B.I., Greten T.F., McGlynn K.A. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer. 2016;122:1757–1765. doi: 10.1002/cncr.29971. PubMed DOI PMC
Hemminki K., Hemminki O., Försti A., Sundquist K., Sundquist J., Li X. Surveillance bias in cancer risk after unrelated medical conditions: Example urolithiasis. Sci. Rep. 2017;7:8073. doi: 10.1038/s41598-017-08839-5. PubMed DOI PMC
Jepsen P., Andersen M.W., Villadsen G.E., Ott P., Vilstrup H. Time-trends in incidence and prognosis of hepatocellular carcinoma in Denmark: A nationwide register-based cohort study. Liver Int. 2017;37:871–878. doi: 10.1111/liv.13340. PubMed DOI
Rigopoulou E.I., Dalekos G.N. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers. 2021;13:1023. doi: 10.3390/cancers13051023. PubMed DOI PMC
Facciorusso A. The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: Recent findings and new perspectives. Curr. Diabetes Rev. 2013;9:382–386. doi: 10.2174/15733998113099990068. PubMed DOI
Yi M., Feng X., Peng W., Teng F., Tang Y., Chen Z. Aspirin for the prevention of hepatocellular carcinoma: An updated meta-analysis with particular focus on patients with chronic liver disease. Eur. J. Clin. Pharmacol. 2022;78:647–656. doi: 10.1007/s00228-021-03247-1. PubMed DOI
Lapumnuaypol K., Tiu A., Thongprayoon C., Wijarnpreecha K., Ungprasert P., Mao M.A., Cheungpasitporn W. Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: A meta-analysis. QJM. 2019;112:421–427. doi: 10.1093/qjmed/hcz039. PubMed DOI
Prasai K., Tella S.H., Yadav S., Kommalapati A., Mara K., Mady M., Hassan M.A., Wongjarupong N., Rodriguez-Payan N., Borad M., et al. Aspirin and Statin Use and the Risk of Gallbladder Cancer. Cancers. 2021;13:1186. doi: 10.3390/cancers13051186. PubMed DOI PMC
Facciorusso A., Abd El Aziz M.A., Singh S., Pusceddu S., Milione M., Giacomelli L., Sacco R. Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis. Cancers. 2020;12:874. doi: 10.3390/cancers12040874. PubMed DOI PMC
Batyrbekova N., Aleman S., Lybeck C., Montgomery S., Duberg A.S. Hepatitis C Virus Infection and the Temporal Trends in the Risk of Liver Cancer: A National Register-Based Cohort Study in Sweden. Cancer Epidemiol. Biomark. Prev. 2020;29:63–70. doi: 10.1158/1055-9965.EPI-19-0769. PubMed DOI
miRNA and lncRNA as potential tissue biomarkers in hepatocellular carcinoma
